Upstream Processing

3D printing offers a new design freedom for bio/pharmaceutical manufacturing: whether for “printing” a solid-dosage drug or for creating a piece of equipment for bio/pharmaceutical laboratories or manufacturing facilities.

The company has launched a comprehensive portfolio of custom cell biology solutions and a new cell-line engineering technology.

Distek, a provider of laboratory testing instruments, added a dual impeller single-use bioreactor (SUB) system to its BIOne portfolio.

Automation in cell-line development and cell culture is leading to more consistent quality while improving efficiency, and, ultimately, speed to market.

A new facility in California will expand Orchard Therapeutic’s capacity to develop and deliver lentiviral vector and gene-corrected hematopoetic stem cells.

Advances in single-use technologies, sensors, and cell retention systems facilitate processes designed for the long run.

Recent equipment and updated product options offer improvement to a range of biopharmaceutical manufacturing tasks.

Survey results and record attendance may show positive signs for established and emerging biopharma regions.

This article will explore the requirements for media and supplements needed to maintain newer cell lines, such as those based on human cells and fungal cells.

The companies partnered to build a 500-L single-use pilot-scale plant for biologics production.

The maturation of single-use technologies presents commercial bioprocessing options for small-volume drug products.

The provider of plant-based ingredients will present recently launched multi-compendial materials for upstream and downstream biopharmaceutical applications.

New products were developed as next-generation process intensification technologies, MilliporeSigma reports.

Sharing of bioprocessing know-how can help resolve pressing industry problems.

Trace elements in raw materials may impact the quality and safety of the finished biologic product, according to industry experts.

Biopharma seeks alternatives that meet the needs for next-gen biologic drug production.

The quality of the cell lines used to manufacture biopharmaceuticals are crucial for the production of high-quality, stable biopharmaceuticals.

Biopharma companies can balance competing demands from patients, investors, and regulators by keeping a focus on science.

Late-stage and commercial biomanufacturing pose a challenge to cell-culture processing.

Understanding differences in bioreactor lifecycle, design space, and product platforms is important for selecting a bioreactor type.

This article discusses affinity capture for tier determination and surveys a broad collection of commonly and less commonly used assays to analyze cell culture media

Transcriptomics plays a role in influencing the production of recombinant therapeutics in microbial and mammalian hosts.

The need to improve and understand processes is moving PAT and more advanced control strategies beyond the lab into manufacturing and downstream applications.

More published data and initial regulatory approvals are needed to drive adoption of continuous bio-manufacturing.

The new platform is expected to speed up cell line development.

Fujifilm acquires cell culture media companies Irvine Scientific Sales Company and IS Japan.

Developments and investments in single-use systems advance upstream biomanufacturing.

Sartorius Stedim Biotech has launched a new automated parallel bioreactor system for perfusion culture.

The contract development and manufacturing organization has expanded biologics capacity at its facility in Berkeley, CA.

Under this agreement, the companies will develop in parallel an antibody drug candidate and cell lines for other potential candidates.